Rhythm Biosciences Ltd
ASX:RHY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (13.8), the stock would be worth AU$-0.25 (243% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -9.6 | AU$0.18 |
0%
|
| Industry Average | 13.8 | AU$-0.25 |
-243%
|
| Country Average | 13.2 | AU$-0.24 |
-237%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Rhythm Biosciences Ltd
ASX:RHY
|
59m AUD | -9.6 | -8.8 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
99.1B USD | 9.3 | 56 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
69.7B EUR | 8.3 | 13.4 | |
| US |
|
Cigna Corp
NYSE:CI
|
72.6B USD | 0 | 12.2 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.1B EUR | 8.5 | 23.3 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
22.7B EUR | 8.8 | 17.9 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.8B USD | 11.8 | 21.4 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.7B USD | 13.2 | 24.7 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.8B EUR | 4 | 11.1 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.6B USD | -62.9 | -27.9 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 5.5 | 13.9 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 8.9 |
| Median | 13.2 |
| 70th Percentile | 19.2 |
| Max | 8 864.3 |
Other Multiples
Rhythm Biosciences Ltd
Glance View
Rhythm Biosciences Ltd. engages in the research, development, and commercialization of medical diagnostics technologies. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-12-07. The firm is engaged in developing and commercializing Australian medical diagnostics technology for sale in domestic and international markets. The Company’s development stage product, ColoSTAT focuses to provide early detection test for colorectal cancer. The Company’s ColoSTAT blood test is used to detect colorectal cancer at all stages, including the early ones. The firm's subsidiary includes Vision Tech Bio Pty Ltd.
